

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIOCON BIOLOGICS INC.,
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

IPR2024-00201
Patent 10,888,601 B2

Petitioner's Amended Mandatory Notices

Biocon Biologics Inc. (“Petitioner”) submits the following amended mandatory notices to identify additional related matters.

A. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1)).

Petitioner Biocon Biologics Inc., Biocon Limited, Biocon Biologics Limited, Biocon Biologics UK Limited, and Biosimilar Collaborations Ireland Limited are real parties-in-interest (“RPIs”) to the current Petition. Biocon Biologics Limited is a subsidiary of Biocon Limited, a publicly traded company. Biocon Biologics UK Limited is a wholly owned subsidiary of Biocon Biologics Limited, and Biosimilar Collaborations Ireland Limited and Biocon Biologics Inc. are wholly owned subsidiaries of Biocon Biologics UK Limited.

Further RPIs include Mylan Pharmaceuticals Inc. (“Mylan”) and Johnson & Johnson. Viatriis Inc. and Mylan Inc. are parent companies of Mylan Pharmaceuticals Inc. Accordingly, Viatriis Inc., Mylan Inc., and Mylan Pharmaceuticals Inc. are identified as RPIs to the current Petition. Momenta Pharmaceuticals, Inc. and Janssen Research & Development LLC are wholly-owned subsidiaries of Johnson & Johnson, a publicly held company. Momenta Pharmaceuticals, Inc., Janssen Research & Development LLC, and Johnson & Johnson are also RPIs to the current Petition.

No other parties exercised or could have exercised control over this Petition; no other parties funded, directed, and controlled this Petition. *See* Trial Practice

Guide, 15-16 (November 2019).

B. RELATED MATTERS (37 C.F.R. § 42.8(b)(2)) (AMENDED).

Petitioner identifies *Samsung Bioepis Co. Ltd. v. Regeneron Pharms., Inc.*, No. IPR2023-00739 (P.T.A.B.), *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2022-01225 (P.T.A.B.), and *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2022-01226 (P.T.A.B.). Petitioner also identifies *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2021-00880 (P.T.A.B.), *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2021-00881 (P.T.A.B.), *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2023-00099 (P.T.A.B.), *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 2023-1395 (Fed. Cir.), *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, No. 2023-1396 (Fed. Cir.), *Regeneron Pharms., Inc. v. Mylan Pharms. Inc.*, 1:22-cv-00061-TSK (N.D.W. Va.); *Regeneron Pharms., Inc. v. Celltrion, Inc.*, 1:23-cv-00089-TSK (N.D.W. Va.); and *Regeneron Pharms., Inc. v. Samsung Bioepis Co. Ltd.*, 1:23-cv-00094-TSK (N.D.W. Va.). To the best of Petitioner's knowledge, the following are additional judicial or administrative matters that would affect, or be affected by, a decision in this proceeding: *Apotex Inc. v. Regeneron Pharmaceuticals, Inc.*, No. IPR2022-01524 (P.T.A.B.), *Samsung Bioepis Co., Ltd. v. Regeneron Pharms., Inc.*, IPR2023-00442 (P.T.A.B.), *Samsung Bioepis Co., Ltd. v. Regeneron Pharms., Inc.*, IPR2023-00884 (P.T.A.B.), *United States v. Regeneron Pharms., Inc.*, No. 1:20-cv-11217-FDS (D. Mass.), and *Horizon Healthcare Servs.,*

Inc. v. Regeneron Pharms., Inc., No. 1:22-cv-10493-FDS (D. Mass.).

U.S. Patent Nos. 9,254,338 B2; 9,669,069 B2; 10,857,205 B2; 10,828,345 B2; 10,130,681 B2; 11,253,572 B2; 11,559,564 B2; 11,707,506 B2; and 11,730,794 B2; and U.S. Patent Application Nos. 17/072,417; 17/112,063; and 18/496,472 each claim the benefit of the '601 patent's purported priority date.

C. LEAD AND BACK-UP COUNSEL AND SERVICE INFORMATION (37 C.F.R. § 42.8(b)(3)-(4)).

Petitioner identifies its lead and backup counsel below.

Lead	Back-Up
Paul J. Molino (Reg. No. 45,350) paul@rmmslegal.com <u>Postal and Hand Delivery Address</u> Rakoczy Molino Mazzochi Siwik LLP 6 West Hubbard Street Chicago, IL 60654 Telephone: (312) 222-6300 Facsimile: (312) 843-6260 <i>Petitioner consents to email service at:</i> MYL_REG_IPR@rmmslegal.com	William A. Rakoczy (<i>pro hac vice</i> pending) wrakoczy@rmmslegal.com Deanne M. Mazzochi (Reg. No. 50,158) dmazzochi@rmmslegal.com Heinz J. Salmen (<i>pro hac vice</i> pending) hsalmen@rmmslegal.com Jeff A. Marx (Reg. No. 56,977) jmarx@rmmslegal.com Eric R. Hunt (<i>pro hac vice</i> pending) ehunt@rmmslegal.com Neil B. McLaughlin (Reg. No. 70,810) nmclaughlin@rmmslegal.com Lauren M. Lesko

	(admitted <i>pro hac vice</i>) llesko@rmmslegal.com L. Scott Beall (Reg. No. 52,601) sbeall@rmmslegal.com Thomas H. Ehrich (Reg. No. 67,122) tehrich@rmmslegal.com Steven J. Birkos (Reg. No. 65,300) sbirkos@rmmslegal.com <u>Postal and Hand Delivery Address</u> Rakoczy Molino Mazzochi Siwik LLP 6 West Hubbard Street Chicago, IL 60654 Telephone: (312) 527-2157 Facsimile: (312) 843-6260
--	---

Please direct all correspondence to lead and back-up counsel at the contact information above. Petitioner also consents to service by email at: MYL_REG_IPR@rmmslegal.com.

Dated: November 29, 2023

Respectfully Submitted,

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

/Paul J. Molino/

Paul J. Molino

Registration No. 45,350

6 West Hubbard Street

Chicago, IL 60654

Telephone: (312) 222-6300

Facsimile: (312) 843-6260

paul@rmmslegal.com

Counsel for Petitioner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a true and correct copy of the foregoing Petitioner's Amended Mandatory Notices was served on November 29, 2023, via electronic mail, to the following counsel of record for Patent Owner:

Adam R. Brausa (Reg. No. 60,287)
Rebecca Weires (Reg. No. 77,895)
Duralyn J. Durie (*pro hac vice* to be filed)
Morrison & Foerster LLP
425 Market Street
San Francisco, CA 94105
Tel: 415.268.6053
Tel: 415.268.6028
Tel: 415.268.6055
abrausa@mofo.com
rweires@mofo.com
ddurie@mofo.com

Kira A. Davis (*pro hac vice* to be filed)
Morrison & Foerster LLP
707 Wilshire Blvd., Suite 6000
Los Angeles, CA 90017
Tel: 213.892.5654
kiradavis@mofo.com

Dated: November 29, 2023

Respectfully Submitted,
RAKOCZY MOLINO MAZZOCHI SIWIK LLP
/Paul J. Molino/
